<p>随着业务可能达到一个重要的里程碑，我们认为有必要更仔细地审视 <strong>ESSA Pharma Inc.（NASDAQ:EPIX）</strong> 的未来前景。ESSA Pharma Inc.是一家临床阶段的制药公司，专注于小分子药物的开发，以治疗前列腺癌。这家市值 7000 万美元的公司在最近的财年中亏损 2900 万美元，最近 12 个月的亏损为 3100 万美元，导致亏损与盈亏平衡之间的差距进一步扩大。许多投资者都在关注 ESSA Pharma 何时能够实现盈利，最大的问题是 “公司何时能够实现盈亏平衡？” 下面我们将提供行业分析师对该公司的预期的高层次总结。</p>
<p>根据覆盖 ESSA Pharma 的 3 位行业分析师的共识，盈亏平衡点即将到来。他们预计公司将在 2026 年遭受最后一次亏损，然后在 2027 年实现 3600 万美元的正利润。因此，预计公司将在大约两年内实现盈亏平衡。为了在 2027 年达到盈亏平衡，公司每年需要多快增长？根据分析师的估计，结果显示他们预计公司年均增长 59%，这一预期非常乐观。如果这个增长率被证明过于激进，公司可能会比分析师预测的更晚实现盈利。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/275296588-earnings-per-share-growth-1-dark/1744712937908?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/275296588-earnings-per-share-growth-1-dark/1744712937908"/></p>
<p>NasdaqCM:EPIX 每股收益增长 2025 年 4 月 15 日</p>
<p>鉴于这是一个高层次的总结，我们不会详细讨论 ESSA Pharma 的公司特定发展，但需要考虑的是，生物技术公司通常现金流波动，这取决于产品类型和公司所处的发展阶段。这意味着，随着公司开始收获早期投资的收益，较大的即将增长率并不罕见。</p>
<p>查看我们对 ESSA Pharma 的最新分析</p>
<p>在结束之前，有一个方面值得提及。ESSA Pharma 目前在其资产负债表上没有债务，这在亏损的生物技术公司中是罕见的，因为这类公司通常相对于其股本有较高的债务。这意味着公司完全依靠其股本投资运营，没有债务负担。这一方面降低了投资于亏损公司的风险。</p>
<h2>下一步：</h2>
<p>本文未涵盖 ESSA Pharma 的一些关键基本面，但我们必须再次强调，这仅仅是一个基本概述。要更全面地了解 ESSA Pharma，请查看 Simply Wall St 上 ESSA Pharma 的公司页面。我们还整理了一份您应该进一步审查的重要因素清单：</p>
<ol>
<li><strong>历史业绩</strong>：ESSA Pharma 过去的表现如何？深入分析过去的业绩记录，并查看我们分析的免费可视化表示以获得更多清晰度。</li>
<li><strong>管理团队</strong>：经验丰富的管理团队能够增强我们对业务的信心——查看 ESSA Pharma 董事会成员及首席执行官的背景。</li>
<li><strong>其他高表现股票</strong>：是否有其他股票提供更好的前景和经过验证的业绩记录？在这里探索我们免费的这些优秀股票列表。</li>
</ol>
<p>如果您想交易 ESSA Pharma，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

ESSA制药

<p>根据分析师的预测，ESSA Pharma Inc.（纳斯达克代码：EPIX）是一家专注于前列腺癌治疗的临床阶段制药公司，预计将在 2027 年前实现盈亏平衡。该公司的市值为 7000 万美元，在过去两个财年中分别报告了 2900 万美元和 3100 万美元的亏损。分析师预计其年增长率将达到 59%，以实现盈利。值得注意的是，ESSA Pharma 没有债务，从而降低了投资风险。为了进行更深入的分析，建议进一步审查公司的历史业绩和管理团队</p>

<p>With the business potentially at an important milestone, we thought we'd take a closer look at <strong>ESSA Pharma Inc.'s (NASDAQ:EPIX)</strong> future prospects. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The US$70m market-cap company posted a loss in its most recent financial year of US$29m and a latest trailing-twelve-month loss of US$31m leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which ESSA Pharma will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.</p>
<div class="lb-trans"><p>随着业务可能达到一个重要的里程碑，我们认为有必要更仔细地审视 <strong>ESSA Pharma Inc.（NASDAQ:EPIX）</strong> 的未来前景。ESSA Pharma Inc.是一家临床阶段的制药公司，专注于小分子药物的开发，以治疗前列腺癌。这家市值 7000 万美元的公司在最近的财年中亏损 2900 万美元，最近 12 个月的亏损为 3100 万美元，导致亏损与盈亏平衡之间的差距进一步扩大。许多投资者都在关注 ESSA Pharma 何时能够实现盈利，最大的问题是 “公司何时能够实现盈亏平衡？” 下面我们将提供行业分析师对该公司的预期的高层次总结。</p>
</div><p>According to the 3 industry analysts covering ESSA Pharma, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$36m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.</p>
<div class="lb-trans"><p>根据覆盖 ESSA Pharma 的 3 位行业分析师的共识，盈亏平衡点即将到来。他们预计公司将在 2026 年遭受最后一次亏损，然后在 2027 年实现 3600 万美元的正利润。因此，预计公司将在大约两年内实现盈亏平衡。为了在 2027 年达到盈亏平衡，公司每年需要多快增长？根据分析师的估计，结果显示他们预计公司年均增长 59%，这一预期非常乐观。如果这个增长率被证明过于激进，公司可能会比分析师预测的更晚实现盈利。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/275296588-earnings-per-share-growth-1-dark/1744712937908" alt="" original-src="https://images.simplywall.st/asset/chart/275296588-earnings-per-share-growth-1-dark/1744712937908"/></p>
<p>NasdaqCM:EPIX Earnings Per Share Growth April 15th 2025</p>
<div class="lb-trans"><p>NasdaqCM:EPIX 每股收益增长 2025 年 4 月 15 日</p>
</div><p>We're not going to go through company-specific developments for ESSA Pharma given that this is a high-level summary, however, take into account that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.</p>
<div class="lb-trans"><p>鉴于这是一个高层次的总结，我们不会详细讨论 ESSA Pharma 的公司特定发展，但需要考虑的是，生物技术公司通常现金流波动，这取决于产品类型和公司所处的发展阶段。这意味着，随着公司开始收获早期投资的收益，较大的即将增长率并不罕见。</p>
</div><p>View our latest analysis for ESSA Pharma</p>
<div class="lb-trans"><p>查看我们对 ESSA Pharma 的最新分析</p>
</div><p>Before we wrap up, there’s one aspect worth mentioning. ESSA Pharma currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.</p>
<div class="lb-trans"><p>在结束之前，有一个方面值得提及。ESSA Pharma 目前在其资产负债表上没有债务，这在亏损的生物技术公司中是罕见的，因为这类公司通常相对于其股本有较高的债务。这意味着公司完全依靠其股本投资运营，没有债务负担。这一方面降低了投资于亏损公司的风险。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>There are key fundamentals of ESSA Pharma which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at ESSA Pharma, take a look at ESSA Pharma's company page on Simply Wall St. We've also put together a list of important factors you should further examine:</p>
<div class="lb-trans"><p>本文未涵盖 ESSA Pharma 的一些关键基本面，但我们必须再次强调，这仅仅是一个基本概述。要更全面地了解 ESSA Pharma，请查看 Simply Wall St 上 ESSA Pharma 的公司页面。我们还整理了一份您应该进一步审查的重要因素清单：</p>
</div><ol>
<li><strong>Historical Track Record</strong>: What has ESSA Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.</li>
<li><strong>Management Team</strong>: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ESSA Pharma's board and the CEO’s background.</li>
<li><strong>Other High-Performing Stocks</strong>: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.</li>
</ol>
<div class="lb-trans"><ol>
<li><strong>历史业绩</strong>：ESSA Pharma 过去的表现如何？深入分析过去的业绩记录，并查看我们分析的免费可视化表示以获得更多清晰度。</li>
<li><strong>管理团队</strong>：经验丰富的管理团队能够增强我们对业务的信心——查看 ESSA Pharma 董事会成员及首席执行官的背景。</li>
<li><strong>其他高表现股票</strong>：是否有其他股票提供更好的前景和经过验证的业绩记录？在这里探索我们免费的这些优秀股票列表。</li>
</ol>
</div><p>If you're looking to trade ESSA Pharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 ESSA Pharma，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

ESSA 制药公司（NASDAQ:EPIX）：分析师是否持乐观态度？